Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott wins innovation award

Abbott wins innovation award

30th October 2008

Abbott has won a major innovation award for the fourth time in six years for its heart disease treatment Xience V.

The 2008 Chicago Innovation Award was awarded to the everolimus eluting coronary stent system, which is a next-generation drug eluting stent Abbott says is a “significant advance in the treatment of coronary artery disease”.

Xience V was approved by the United States Food and Drug Administration (FDA) and launched in July 2008.

Some 13 million Americans have coronary artery disease, which is the leading cause of death for both men and women in the US.

Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart, while a drug eluting stent like Xience V releases a medication – everolimus, in this case – in a controlled manner to prevent the artery from becoming blocked again following a stent procedure.

Abbott says it is the only drug eluting stent to show superiority over the previous market-leading drug eluting stent in two randomised, pivotal clinical trials.

In the three months since its launch it has become the market-leading drug eluting stent.

The company designs and manufactures pharmaceuticals and medical products, including nutritionals, devices and diagnostics. It was founded more than a century ago.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.